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Psychosis in Systemic Lupus Erythematosus: Results From 
an International Inception Cohort Study
John G. Hanly,1 Qiuju Li,2 Li Su,2 Murray B. Urowitz,3 Caroline Gordon,4 Sang-Cheol Bae,5 Juanita Romero-Diaz,6 
Jorge Sanchez-Guerrero,3 Sasha Bernatsky,7 Ann E. Clarke,8 Daniel J. Wallace,9 David A. Isenberg,10 
Anisur Rahman,10 Joan T. Merrill,11 Paul R. Fortin,12 Dafna D. Gladman,3 Ian N. Bruce,13 Michelle Petri,14  
Ellen M. Ginzler,15 M. A. Dooley,16 Kristjan Steinsson,17 Rosalind Ramsey-Goldman,18 Asad A. Zoma,19 
Susan Manzi,20 Ola Nived,21 Andreas Jonsen,21 Munther A. Khamashta,22 Graciela S. Alarcón,23  
Ronald F. van Vollenhoven,24 Cynthia Aranow,25 Meggan Mackay,25 Guillermo Ruiz-Irastorza,26  
Manuel Ramos-Casals,27 S. Sam Lim,28 Murat Inanc,29 Kenneth C. Kalunian,30 Soren Jacobsen,31  
Christine A. Peschken,32 Diane L. Kamen,33 Anca Askanase,34 Chris Theriault,1 and Vernon Farewell2
Objective. To determine, in a large, multiethnic/multiracial, prospective inception cohort of patients with systemic 
lupus erythematosus (SLE), the frequency, attribution, clinical, and autoantibody associations with lupus psychosis 
and the short- and long- term outcomes as assessed by physicians and patients.
Methods. Patients were evaluated annually for 19 neuropsychiatric (NP) events including psychosis. Scores on 
the Systemic Lupus Erythematosus Disease Activity Index 2000, the Systemic Lupus International Collaborating Clin-
ics/American College of Rheumatology Damage Index, and the Short Form 36 (SF- 36) were recorded. Time to event 
and linear regressions were used as appropriate.
Results. Of 1,826 SLE patients, 88.8% were female and 48.8% were Caucasian. The mean ± SD age was 35.1 ± 
13.3 years, the mean ± SD disease duration was 5.6 ± 4.2 months, and the mean ± SD follow- up period was 7.4 ± 4.5 
years. There were 31 psychotic events in 28 of 1,826 patients (1.53%), and most patients had a single event (26 of 28 
[93%]). In the majority of patients (20 of 25 [80%]) and events (28 of 31 [90%]), psychosis was attributed to SLE, usually 
either in the year prior to or within 3 years of SLE diagnosis. Positive associations (hazard ratios [HRs] and 95% confi-
dence intervals [95% CIs]) with lupus psychosis were previous SLE NP events (HR 3.59 [95% CI 1.16–11.14]), male sex 
(HR 3.0 [95% CI 1.20–7.50]), younger age at SLE diagnosis (per 10 years) (HR 1.45 [95% CI 1.01–2.07]), and African 
ancestry (HR 4.59 [95% CI 1.79–11.76]). By physician assessment, most psychotic events resolved by the second 
annual visit following onset, in parallel with an improvement in patient- reported SF- 36 summary and subscale scores.
Conclusion. Psychosis is an infrequent manifestation of NPSLE. Generally, it occurs early after SLE onset and has 
a significant negative impact on health status. As determined by patient and physician report, the short- and long- 
term outlooks are good for most patients, although careful follow- up is required.
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INTRODUCTION
Neuropsychiatric (NP) events are one of the features of sys-
temic lupus erythematosus (SLE), but their frequency and attri-
bution to SLE or other causes is variable. Overall, approximately 
one- third are caused directly by SLE (1), but for individual mani-
festations this varies between 0% and 100% (2,3). The outcome 
for individual NPSLE manifestations, especially rare NP events, is 
derived from observational cohorts of well- characterized patients 
followed up over prolonged periods.
One of the rarer NP events is lupus psychosis, which is part 
of both the American College of Rheumatology (ACR) (4) and the 
Systemic Lupus International Collaborating Clinics (SLICC) (5) 
classification criteria for SLE. Characterized by delusions and hal-
lucinations, it is a dramatic presentation of NPSLE (6,7). It is one 
of the few manifestations of nervous system disease in SLE asso-
ciated, although inconsistently, with a lupus- specific autoantibody 
against ribosomal P (8–10). The infrequent occurrence of psycho-
sis has limited the number of clinical studies, and most consist of 
case series obtained by review of medical records. In the present 
study of lupus psychosis, we determined its frequency, attribu-
tion, clinical, and autoantibody associations and the outcome 
assessed by physicians and patients in a large, multiethnic/multi-
racial, prospective inception cohort of SLE patients.
PATIENTS AND METHODS
Research study network. The study was conducted by 
the SLICC (11), a network of 53 investigators in 43 academic 
medical centers in 16 countries. The current study involved 31 
centers in 10 countries. Data were collected per protocol at 
enrollment and annually, submitted to the coordinating center 
in  Halifax, Nova  Scotia, Canada, and entered into an Access 
database. Appropriate procedures ensured data quality, man-
agement, and security. The Nova Scotia Health Authority central 
zone Research Ethics Board, Halifax, and each of the participat-
ing centers’  institutional research ethics review boards approved 
the study.
Patients. Patients fulfilled the ACR classification criteria for 
SLE (4), which served as the date of diagnosis, and provided writ-
ten informed consent. Enrollment was permitted up to 15 months 
following the diagnosis. Demographic variables, educ ation, and 
medication history were recorded. Lupus- related vari ables included 
the Systemic Lupus Erythematosus Disease Activity Index 2000 
(SLEDAI- 2K) (12) and the SLICC/ACR Damage Index (SDI) (13). 
Laboratory testing required to determine the SLEDAI- 2K and SDI 
scores was done at each center.
NP events. An enrollment window extended from 6 months 
prior to the diagnosis of SLE up to the actual enrollment date. 
NP events were characterized within this window using the ACR 
case definitions for 19 NP syndromes (14). The clinical diagnosis 
was supported by investigations, if warranted, as per the guide-
lines. Patients were reviewed annually within a 6- month window 
around the assessment date. New NP events and the status of 
previous NP events since the last study visit were determined at 
each assessment.
The ACR case definition for psychosis (14) includes the fol-
lowing: 1) delusions or hallucinations without insight; 2) causing 
clinical distress or impairment in social, occupational, or other rel-
evant areas of functioning; 3) disturbance should not occur exclu-
sively during delirium; and 4) not better accounted for by another 
mental disorder. Recurring episodes of psychosis and other NP 
events within the enrollment window or within a follow- up assess-
ment period were recorded once for that period of observation. 
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The date of the first episode was taken as the onset of the event. 
Once an NP event had resolved, a subsequent event of the same 
type was recorded as a new event.
Attribution of NP events. Decision rules used to 
determine the attribution of NP events were similar to those 
reported in other publications concerning the SLICC NPSLE 
inception cohort (15,16). We considered 3 factors. The first was 
the temporal onset of NP event(s) in relation to the diagnosis 
of SLE, and the second concerned concurrent non- SLE fac-
tor(s), such as potential causes (“exclusions”) or contributing 
factors (“associations”) for each NP syndrome in the glossary 
for the ACR case definitions of NP events (14). For psychosis, 
the prespecified potential alternative causes (exclusions) were 
1) primary psychotic disorder unrelated to SLE (e.g., schiz-
ophrenia), 2) substance- or drug- induced psychotic disorder, 
and 3) psychologically mediated reaction to SLE (brief reactive 
psychosis with major stressor); the prespecified potential con-
tributing factors (associations) were 1) marked psychosocial 
stress and 2) corticosteroids. For the third and final factor, we 
identified “common” NP events in normal population controls 
as described by Ainiala et  al (17). These included isolated 
headaches, anxiety, and mild depression (mood disorders fail-
ing to meet criteria for “major depressive- like episodes”), mild 
cognitive impairment (deficits in less than 3 of the 8 specified 
cognitive domains), and polyneuropathy without electrophys-
iologic confirmation. Using these 3 factors, we used 2 attri-
bution decision rules of different stringency (models A and B) 
(15,16).
Attribution model A (most stringent). NP events that had 
their onset within the enrollment window and had no exclusions 
or associations and were not one of the NP events identified by 
Ainiala et al (17) were attributed to SLE.
Attribution model B (least stringent). NP events that had 
their onset within 10 years of the diagnosis of SLE and were still 
present within the enrollment window and had no exclusions and 
were not one of the NP events identified by Ainiala et al (17) were 
attributed to SLE.
By definition, all NP events attributed to SLE using model A 
were similarly attributed using model B. Events that did not fulfill 
these criteria were classified as non- SLE NP events.
Outcome of psychosis. For every NP event, a physician- 
generated 7- point Likert scale was completed at each follow- up 
assessment until resolution of the event or patient demise (1 = 
patient demise, 2 = much worse, 3 = worse, 4 = no change, 
5 = improved, 6 = much improved, 7 = resolved) (18). A patient- 
generated Short Form 36 (SF- 36) questionnaire was also com-
pleted at each assessment and provided subscale scores, mental 
component summary (MCS) and physical component summary 
(PCS) scores (18,19) that were unavailable to physicians at their 
 assessments.
Autoantibodies. Plasma lupus anticoagulant, serum IgG 
anticardiolipin, anti–β2- glycoprotein I, anti–ribosomal P (anti- P), 
and anti–NR2 glutamate receptor antibodies were measured at 
the Oklahoma Medical Research Foundation, as described (20–
23).
Statistical analysis. Since there were only 15 patients with 
psychosis attributed to SLE by model A, we used attribution model 
B and Cox regression to analyze time to first SLE psychosis. This 
included onset of NP events prior to SLE diagnosis in order to 
capture all NP events potentially related to the risk of psychosis.
Hazard ratios (HRs) and 95% confidence intervals (95% CIs) 
were calculated. Covariates examined included sex, race/ethnic-
ity, SLICC sites, postsecondary education, number of ACR criteria 
at enrollment (excluding neurologic disorder), SDI (without NP var-
iables), other concurrent NP events, and, as continuous variables, 
age at SLE diagnosis, disease duration (in years), and SLEDAI- 2K 
score (without NP variables). Binary variables indicating autoan-
tibodies present at baseline and follow- up assessments were 
defined when available. Time- varying variables, other than those 
related to autoantibodies, were updated at each assessment. 
When examining the time- varying version of the autoantibody 
variables, autoantibody data in the period before enrollment were 
imputed by their values at enrollment, while autoantibody data 
at follow- up assessments were imputed by the last observation 
carried forward method. Kaplan- Meier estimates of the survivor 
function for the time until resolution of psychosis were calculated. 
For analyses of longitudinal SF- 36 subscale and summary scores, 
linear regression with generalized estimating equations allowed for 
correlation of observations within patients, and adjustment vari-
ables included time/visit, sex, age at SLE diagnosis, race/ethnic-
ity/location, education, SLEDAI- 2K and SDI scores (without NP 
variables), corticosteroids, antimalarials, and immunosuppressant 
use since last assessment.
RESULTS
Patient recruitment and assessments. A total of 1,826 
patients were recruited between October 1999 and December 
2011, from centers in the US (n = 539 [29.5%]), Europe (n = 477 
[26.1%]), Canada (n = 418 [22.9%]), Mexico (n = 223 [12.2%]), 
and Asia (n = 169 [9.3%]) (Table 1). The number of patient assess-
ments varied from 1 to 19 with a mean ± SD follow- up period of 
7.4 ± 4.5 years, and final assessment follow- up was in March 
2017.
NP manifestations. NP events (≥1) occurred in 951 of 
1,826 patients (52.1%), and 488 of 1,826 patients (26.7%) had 
≥2 events during the study period. There were 1,902 unique NP 
events, encompassing all 19 NP syndromes in the ACR case defi-
nitions (14). The proportion of NP events attributed to SLE varied 
from 17.8% (attribution model A) to 31.1% (attribution model B) 
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and occurred in 13.3% of patients (model A) to 21.1% of patients 
(model B). Of the 1,902 unique NP events, 1,742 (91.6%) involved 
the central nervous system and 160 (8.4%) involved the peripheral 
nervous system (14). The classification of events as diffuse and 
focal was 1,471 (77.3%) and 431 (22.7%), respectively (16).
Psychosis. Among 28 of 1,826 patients with psychosis 
(1.53%), 26 of 28 (93%) had a single psychotic event, while 1 
patient had 2 discrete events and 1 patient had 3 discrete events. 
The majority of patients had psychosis attributed to SLE (15 of 28 
[54%] using attribution model A and 25 of 28 [89%] using attri-
bution model B). Patients with lupus psychosis (model B) were 
located in centers in Europe (9 patients), Canada (6 patients), the 
US (5 patients), Mexico (4 patients), and Asia (1 patient). There 
was no significant association between location and risk of SLE 
psychosis (P = 0.53 in Cox regression) taking into account the 
number of patients and the duration of follow- up at each site. The 
majority of patients with lupus psychosis (20 of 25 [80%]) had their 
first episode either in the year prior to or within 3 years following 
the diagnosis of SLE (Figure 1). There were 31 psychotic events, 
of which 16 of 31 (52%) and 28 of 31 (90%) were attributed to SLE 
using attribution models A and B, respectively. The earliest psy-
chotic episode occurred 2 months prior to the diagnosis of SLE.
Clinical and laboratory associations with lupus psy-
chosis. Using Cox regression, we looked for associations with 
the risk of the first episode of psychosis attributed to SLE using 
attribution model B. Univariate analysis revealed positive associ-
ations with male sex (HR 2.58 [95% CI 1.04–6.41]), younger age 
at diagnosis (per 10 years) (HR 1.36 [95% CI 1.0–1.88]), African 
ancestry (HR 4.80 [95% CI 1.86–12.40]), in particular for patients 
outside the US (HR 5.53 [95% CI 1.86–16.42]), concurrent other 
central (HR 3.86 [95% CI 1.27–11.70]) or diffuse (HR 6.36 [95% CI 
2.12–19.12]) NP events (mood disorder, acute confusional state) 
attributed to SLE, and presence of anti- P antibodies at the enroll-
ment visit into the cohort (HR 3.31 [95% CI 1.19–9.21]) and over 
time (HR 3.13 [95% CI 1.15–8.56]).
Important variables identified in univariate analyses, in 
particular for African patients outside the US, were included 
in multivariate analyses, excluding antibody vari ables due to 
reduced sample size consequent to missing data (Table  2). 
The significant positive associations with lupus psychosis were 
similar, namely, prior SLE NP events (HR 3.59 [95% CI 1.16–
Table  1. Demographics, clinical features, medications, and 
autoantibodies in the 1,826 patients at enrollment* 
Sex, no. (%)
Female 1,622 (88.8)
Male 204 (11.2)
Age, years 35.1 ± 13.3
Race/ethnicity, no. (%)
Caucasian 891 (48.8)
African 306 (16.8)
Hispanic 282 (15.4)
Asian 275 (15.1)
Other 72 (3.9)
Marital status, no. (%)
Single 818 (44.9)
Married 766 (42.0)
Other 238 (13.1)
Postsecondary education, no. (%) 1,064 (61.9)
Disease duration, months 5.6 ± 4.2
ACR SLE criteria met 4.9 ± 1.1
ACR SLE criteria, no. (%)
Malar rash 660 (36.1)
Discoid rash 227 (12.4)
Photosensitivity 652 (35.7)
Oral/nasal ulcers 677 (37.1)
Serositis 502 (27.5)
Arthritis 1,368 (74.9)
Renal disorder 510 (27.9)
Neurologic disorder 88 (4.8)
Hematologic disorder 1,129 (61.8)
Immunologic disorder 1,392 (76.2)
Antinuclear antibody positivity 1,731 (94.8)
SLEDAI- 2K score 5.3 ± 5.4
SLICC/ACR Damage Index score† 0.32 ± 0.74
Medications, no. (%)
Corticosteroids 1,284 (70.3)
Antimalarials 1,231 (67.4)
Immunosuppressants 732 (40.1)
ASA 261 (14.3)
Antidepressants 183 (10.0)
Warfarin 99 (5.4)
Anticonvulsants 80 (4.4)
Antipsychotics 12 (0.7)
Autoantibody positivity, no./total no. (%)
Lupus anticoagulant 241/1,174 (20.5)
Anticardiolipin 138/1,142 (12.1)
Anti–β2- glycoprotein I 163/1,142 (14.3)
Anti–ribosomal P 112/1,136 (9.9)
Anti–NR2 glutamate receptor 130/1,064 (12.2)
* Except where indicated otherwise, values are the mean ± SD. 
SLEDAI- 2K = Systemic Lupus Erythematosus Disease Activity Index 
2000; ASA = acetylsalicylic acid. 
† The Systemic Lupus International Collaborating Clinics/American 
College of Rheumatology (SLICC/ACR) Damage Index score was not 
available for 1,057 patients at the enrollment visit when disease 
duration was <6 months. 
Table 1. (Cont’d)
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11.14]), male sex (HR 3.0 [95% CI 1.20–7.50]), younger age 
at SLE diagnosis (per 10 years) (HR 1.45 [95% CI 1.01–2.07]), 
and African ancestry (HR 4.59 [95% CI 1.79–11.76]). Further, 
after adjustment for the demographic predictors in Table  2 
(sex, age at SLE diagnosis, and race/ethnicity), anti- P anti-
bodies at enrollment (HR 2.29 [95% CI 0.81–6.46], P = 0.11) 
and over time (HR 2.17 [95% CI 0.79–5.97], P = 0.13) were no 
longer significantly associated with the risk of lupus psychosis.
Treatment of SLE psychosis. The treatment of individ-
ual patients was at the discretion of their attending rheumatol-
ogists and was predicated on the overall needs of the patient 
and not only on the psychotic event. The following therapies 
were used during the time of the first psychotic events: corti-
costeroids in 23 of 28 patients (82.1%) with a mean ± SD dose 
of prednisone of 21.9 ± 14.9 mg/day, immunosuppressants 
(cyclophosphamide, azathioprine, methotrexate, mycophe-
nolate mofetil) in 17 of 28 patients (60.7%), biologic agents 
in 1 of 28 patients (3.6%), antipsychotic drugs in 19 of 28 
patients (67.9%), antidepressants in 11 of 28 patients (39.3%), 
and either/both antipsychotic drugs and antidepressants in 22 
of 28 patients (78.6%). In 13 of 28 patients (46.4%), cortico-
steroids had been started prior to the onset of psychosis with 
a mean ± SD dose of 20.3 ± 13.6 mg/day.
Clinical outcome and health- related quality of life 
(HRQoL) in patients with lupus psychosis. A summary of 
physician assessments of outcome of lupus psychosis is illus-
trated in Figure 2. More than 80% of the psychotic events had 
resolved by the second annual assessment following onset of the 
event (Figure  2A). Likewise, the maximum and minimum Likert 
scores over the duration of follow- up illustrate that the majority of 
psychotic events either improved or resolved during the period of 
observation (Figure 2B).
The mean ± SD SF- 36 PCS and MCS scores are shown in 
Figure 3A for 4 patient groups. Group 1 consisted of patients with 
onset of lupus psychosis since last assessment or with an ongo-
ing psychotic event (n = 29 visits). Group 2 consisted of patients 
with onset of other NP events since last assessment or ongoing 
other NP event(s), including non- SLE psychosis (n = 3,379 visits). 
Group 3 consisted of patients with no NP events since last assess-
ment and no ongoing NP event(s) but with a history of  previous NP 
event(s) (n = 2,180 visits). Group 4 consisted of patients who never 
Figure  1. Relationship between the time of onset of lupus 
psychosis and diagnosis of systemic lupus erythematosus (SLE).
Table 2. Predictors of lupus psychosis by multivariate analysis* 
Predictor, factor level HR (95% CI) P
Other concurrent NP events
No concurrent NP events 1
Any unresolved NP events attributed to SLE 3.59 (1.16–11.14) 0.027†
Any unresolved NP events not attributed to 
SLE but no events attributable to SLE
0.89 (0.21–3.82) 0.087†
Global test – 0.082
Sex
Female 1
Male 3.0 (1.20–7.50) 0.019†
Younger age at SLE diagnosis (per 10 years) 1.45 (1.01–2.07) 0.044†
Race
Caucasian 1
African 4.59 (1.79–11.76) 0.002†
Asian and other 0.93 (0.24–3.64) 0.913†
Hispanic 1.37 (0.39–4.85) 0.622†
Global test – 0.005
* HR = hazard ratio; 95% CI = 95% confidence interval; NP = neuropsychiatric; SLE = systemic lupus erythematosus. 
† By Wald’s test. 
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had NP event(s) (n = 5,893 visits). The lowest summary scores 
were in groups 1 and 2 (global P < 0.0001 in the multivariate analy-
ses), and the negative impact on HRQoL affected all 8 subscales of 
the SF- 36 as shown in the accompanying spidergram (Figure 3B).
To determine if there was a persistent change in HRQoL 
following physician- determined resolution of lupus psychosis, 
patient- generated SF- 36 scores were compared in 2 groups. The 
psychosis group consisted of patients with onset of lupus psy-
chosis since last assessment up to its resolution (n = 29 visits). 
The resolved group consisted of patients with resolution of lupus 
psychosis up to their last follow- up visit or recurrence of psychosis 
(n = 112 visits). If the psychotic event had both onset and reso-
lution in the same interval prior to assessment, SF- 36 scores at 
that assessment were included only in the psychosis group. As 
illustrated in Figure 4A, there was substantial improvement both 
in MCS scores (mean difference 7.01) and in PCS scores (mean 
Figure 2. Physician- determined outcome of lupus psychosis. A, Survival curve for resolution. B, Likert scale scores. The highest and lowest scores 
over the duration of follow- up are shifted to the right, indicating improvement. SLE = systemic lupus erythematosus; 95% CI = 95% confidence interval.
Figure 3. Association of Short Form 36 (SF- 36) summary and subscale scores with lupus psychosis. A, Mean ± SD physical component 
summary (PCS) and mental component summary (MCS) scores in 4 groups of patients with systemic lupus erythematosus (SLE). Group 1 
consisted of patients with onset of lupus psychosis since last assessment or with an ongoing psychotic event (n = 29 visits). Group 2 consisted 
of patients with onset of other neuropsychiatric (NP) events since last assessment or ongoing other NP event(s), including non- SLE psychosis 
(n = 3,379 visits). Group 3 consisted of patients with no NP events since last assessment and no ongoing NP event(s) but with a history of 
previous NP event(s) (n = 2,180 visits). Group 4 consisted of patients who never had NP event(s) (n = 5,893 visits). The numbers of assessments 
contributing to each bar are aggregated for patients over time. Global P values in the multivariate analyses are shown. B, Comparison of 
individual subscale scores in the same 4 patient groups. SF- 36 subscales are as follows: PF = physical function; RP = role physical; BP = bodily 
pain; GH = general health; VT = vitality; SF = social function; RE = role emotion; MH = mental health.
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difference 4.34) and in all subscales of the SF- 36 (Figure 4B) con-
current with resolution of lupus psychosis.
DISCUSSION
In a large international inception cohort study of SLE patients, 
we have prospectively documented the frequency, associations, 
and outcomes of psychotic events during a mean follow- up period 
of 7.4 years. Our findings confirm and expand upon the results 
of previous cross- sectional and historical studies of psychosis in 
SLE (6–8,24,25). The majority of psychotic events were directly 
attributed to SLE, had a tendency to occur early in the course of 
the disease, and were more frequent in male patients. Psychosis 
was also more frequent in patients of African ancestry, as is also 
the case for non- SLE patients with the same race/ethnicity (26). 
The outcome of lupus psychosis, as determined by both physi-
cians and patients, was positive and emphasizes the importance 
of diagnosing and treating this rare manifestation of NPSLE.
Studies of NPSLE conducted prior to the introduction in 1999 
of the ACR case definitions for NPSLE did not have a uniform 
definition for psychosis. Using the ACR case definition, the fre-
quency of psychosis has been reported to vary between 0% and 
17.1% (6,17,27–30), and in our study it was 1.53% (28 of 1,826 
patients). Using a well- defined process for determining attribution, 
we confirmed that the majority of psychotic events were due to 
SLE. In keeping with other NPSLE events and with other severe 
SLE manifestations such as nephritis (31), there was a tendency 
for psychosis to occur early in the disease course, usually within 
the first 3 years following the diagnosis of SLE. Univariate analysis 
identified significant associations between lupus psychosis and 
anti- P antibodies, although following adjustment for demographic 
variables, the 95% CIs around HRs were wide and included the 
null value, precluding a definitive conclusion regarding association 
of these autoantibodies with psychosis. This is consistent with an 
earlier report on NP events in the SLICC inception cohort (32).
The potential role of corticosteroids must also be consid-
ered. In the current study, exposure to corticosteroids prior to 
lupus psychosis occurred in less than half of the initial events. 
As per the ACR case definition for psychosis (14), the concur-
rent use of corticosteroids at the onset of psychosis was identi-
fied as an association rather than as a firm exclusion, indicating 
uncertainty about the role of corticosteroids in individual cases 
and to allow flexibility for determining attribution. Although NP 
symptoms have been reported with all types and doses of cor-
ticosteroids (33),  including psychosis following intraarticular ste-
roid injections (34,35), in general the dose of corticosteroids is 
the most important risk factor. In the Boston Collaborative Drug 
Surveillance Program (36), the frequency of psychiatric symp-
toms of any type was 18.6% in patients receiving >80 mg/day of 
prednisone, 4.6% in patients receiving 40–80 mg/day, and 1.3% 
in those receiving <40 mg/day. In the current study, exposure 
to corticosteroids prior to lupus psychosis was in the lowest of 
these dose ranges.
Although the somatic toxicities of corticosteroids are well 
described, the literature on NP effects is sparse. Their reported 
frequency varies widely from 2% to 60% (36–38), and symp-
toms include affective, behavioral, and cognitive manifestations 
(33). Moreover, the term “steroid psychosis” has been used to 
capture a heterogeneous group of NP effects and is not sup-
ported by validated diagnostic criteria, and previous studies 
Figure 4. Long- term change in Short Form 36 (SF- 36) summary and subscale scores following resolution of lupus psychosis. A, Mean ± SD 
physical component summary (PCS) and mental component summary (MCS) scores in 2 groups of patients with systemic lupus erythematosus. 
The psychosis group consisted of patients with onset of lupus psychosis since last assessment up to its resolution (n = 29 visits). The resolved 
group consisted of patients with resolution of lupus psychosis up to their last follow- up visit or recurrence of psychosis (n = 112 visits). If the 
psychotic event had both onset and resolution in the same interval prior to assessment, SF- 36 scores at that assessment were included only in 
the psychosis group. The numbers of assessments contributing to each bar are aggregated for patients over time. B, Comparison of individual 
subscale scores in the same 2 patient groups. SF- 36 subscales are as follows: PF = physical function; RP = role physical; BP = bodily pain; GH 
= general health; VT = vitality; SF = social function; RE = role emotion; MH = mental health.
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have included many patients who were not psychotic. The ACR 
case definition for psychosis (14), used in the current study, 
is based on the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition (DSM- IV) (39). In a previous study of 
2,069 patients who received corticosteroids, only 3 (0.14%) 
developed psychosis according to DSM- IV criteria (40).
One of the major advantages of our prospective study 
was the ability to document the short- term impact and long- 
term outcome of lupus psychosis from the perspectives of 
both the physician and the patient. In keeping with previous 
studies (6,7), the physician assessments indicated resolution 
in the majority of cases with very few recurrences. Using a 
previously validated approach to measure the clinical out-
come of NP events in SLE (18), we used summary and sub-
scale scores of the SF- 36 to assess the patient perspective. 
This is important because physician and patient assessment 
of outcome for other manifestations of SLE (41) and some NP 
events (42) may be discrepant. Although the greatest impact 
was on MCS scores, it was apparent that all subscales of 
the SF- 36 were negatively impacted in patients with lupus 
psychosis. However, following treatment and in keeping with 
physician assessment of outcome, the patient- generated SF- 
36 scores showed a remarkable reversal when averaged over 
time.
There are some limitations to the current study. First, the 
small number of patients with lupus psychosis limited our abil-
ity to precisely estimate potential associations with clinical or 
laboratory variables of interest. However, most of the previ-
ous studies have had an even smaller sample size, and the 
SLICC cohort is the largest inception cohort of SLE patients. 
Second, specialized investigations such as advanced neuro-
imaging or cytokine profiling of cerebrospinal fluid were not 
routinely performed but were left to the discretion of individual 
investigators, which reflects what is done in clinical practice, 
a key component of our overall SLICC protocol. Third, the 
observational cohort study design precludes determination of 
optimal therapeutic regimens for lupus psychosis but instead 
reflects current standard of care. Despite these limitations, the 
study provides encouraging data on the outcome of this rare 
but potentially devastating manifestation of NPSLE.
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